ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elacestrant

Also written as “Elacestrant”, “RAD1901” and “Elacestrant dihydrochloride”.

Its studies are mostly in Breast Neoplasms · Hot Flashes, led by 3 companies.

Drug pageElacestrant: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 3, 201812 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Menarini Group95 open or runningphase 3since Dec 3, 2018Dec 31, 2014Nov 2026phase 2 · NCT05596409
Radius Pharmaceuticalsits history only20 open or runningphase 2since Mar 6, 2009Mar 6, 2009none ahead
Criteriumits history only10 open or runningphase 2since Dec 30, 2020Dec 30, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Menarini Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 31, 2014First study: phase 1 study in Advanced ER+, HER2-Negative Breast CancerFirst studyNCT02338349 · 57 enrolled · United States
  2. Jan 6, 2016Phase 1 study in Breast NeoplasmsNCT02650817 · 16 enrolled · Belgium, Netherlands
  3. Jun 9, 2016Named elacestrantINNProposed as its International Nonproprietary Name in WHO's List 115 · before, RAD1901
  4. Dec 3, 2018Phase 3 study in Breast NeoplasmsNCT03778931 · 478 enrolled · United States, Argentina, Australia and more
  5. May 16, 2022Phase 2 study in Breast NeoplasmsNCT05386108 · 73 planned · United States, Belgium, France and more
  6. Sep 22, 2022Phase 2 study in Breast NeoplasmsNCT05563220 · 435 enrolled · United States, Argentina, Australia and more
  7. Oct 24, 2022Phase 2 study in Breast NeoplasmsNCT05596409 · 61 enrolled · United States, Brazil, Bulgaria and more
  8. Nov 6, 2023Phase 1 study in Breast NeoplasmsNCT06126575 · 16 enrolled · United States
  9. Jul 1, 2024Phase 3 study in Breast NeoplasmsNCT06492616 · 4,556 enrolled · United States, Argentina, Australia and more
  10. Aug 10, 2026Phase 2 study in Breast NeoplasmsNCT07766018 · 70 planned · Japan

Ahead

  1. Nov 2026Primary completion: phase 2 study in Breast NeoplasmsNCT05596409
  2. Dec 2026Primary completion: phase 2 study in Breast NeoplasmsNCT05386108
  3. Dec 27, 2026Primary completion: phase 2 study in Breast NeoplasmsNCT05563220
  4. Oct 2028Primary completion: phase 2 study in Breast NeoplasmsNCT07766018

TargetBeta

ESR1 →read by rule
“An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity”NCIt, by rule
“Estrogen receptor alpha degrader; Estrogen receptor alpha degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 9 Menarini Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07766018Breast Neoplasms · Japan2RecruitingOct 202870
NCT06492616Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAug 20294,556
NCT06126575Breast Neoplasms · United States1CompletedNov 11, 202416
NCT05596409Breast Neoplasms · United States, Brazil, Bulgaria and more2Active, not recruitingNov 202661
NCT05563220Breast Neoplasms · United States, Argentina, Australia and more2Active, not recruitingDec 27, 2026435
NCT05386108Breast Neoplasms · United States, Belgium, France and more2RecruitingDec 202673
NCT03778931Breast Neoplasms · United States, Argentina, Australia and more3CompletedAug 24, 2021478
NCT02650817Breast Neoplasms · Belgium, Netherlands1CompletedAug 30, 201816
NCT02338349Advanced ER+, HER2-Negative Breast Cancer · United States1CompletedSep 201957

How it is read

Names in the registry

  • “Elacestrant”, 8 entries
  • “RAD1901”, 6 entries
  • “Elacestrant dihydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.